Quantum BioPharma Ltd.
QNTMNASDAQHealthcareBiotechnology
Previous close
$3.44
$0.00 · 0.00%
QNTM company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
26
Expensive
Momentum
17
Strong Down
Sentiment
52
Mixed
Risk resilience
37
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteQuantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- Zeeshan Saeed
- Listed since
- Jun 8, 2018
- Employees
- 17
Market position
Day range
Current $3.44
52-week range
Current $3.44
- Open
- $3.37
- Previous close
- $3.44
- Volume
- 137.94K
- 0.44× average
- Average volume
- 316.86K
- Average daily volume
- Market cap
- 22.01M USD
- Beta
- 0.43
- Market reference 1
- 50-day average
- $3.3954
- +1.31% above average
- 200-day average
- $5.163
- -33.37% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -0.61×
- P/B (TTM)
- 2.88×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0.12×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.76M USD | 6.08M USD | 3.86M USD | 6.91M USD | 6.33M USD |
| Selling, general, and administrative | 12.01M USD | 9.31M USD | 13.2M USD | 15.98M USD | 23.37M USD |
| Operating expenses | 15.3M USD | 16.14M USD | 23.79M USD | 27.43M USD | 33.74M USD |
| Interest income | 236.08K USD | 572.89K USD | 786.36K USD | 367.74K USD | 1.29K USD |
| Interest expense | 618.64K USD | 47.58K USD | 299 USD | 48.82K USD | 69.4K USD |
| Depreciation and amortization | 545.78K USD | 490.57K USD | 2.51M USD | 4.54M USD | 4.05M USD |
| Operating income | −15.3M USD | −16.14M USD | −23.79M USD | −27.43M USD | −33.74M USD |
| Net income | −26.18M USD | −14.2M USD | −17.9M USD | −23.61M USD | −35.29M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 7 misses, 1 met estimate
- Average EPS surprise
- -304.03%
- 11 comparable reports
- Latest EPS result
- -0.47
- Estimate -0.41 · Miss by 14.19%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
QNTM news
QNTM peers
ETFs holding QNTM
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research QNTMresearch.disclaimer